153 related articles for article (PubMed ID: 38261131)
1. AOTMiT reimbursement recommendations compared to other HTA agencies.
Mela A; Lis D; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Drop B; Blicharski T; Niewada M
Eur J Health Econ; 2024 Jan; ():. PubMed ID: 38261131
[TBL] [Abstract][Full Text] [Related]
2. Reimbursement decision-making system in Poland systematically compared to other countries.
Mela A; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Jabłoński M; Niewada M
Front Pharmacol; 2023; 14():1153680. PubMed ID: 37900165
[No Abstract] [Full Text] [Related]
3. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
Kawalec P; Malinowski KP
Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
5. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.
Kolasa K; Schubert S; Manca A; Hermanowski T
Health Policy; 2011 Oct; 102(2-3):145-51. PubMed ID: 21641074
[TBL] [Abstract][Full Text] [Related]
6. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
8. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
9. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
Kawalec P; Malinowski KP; Trąbka W
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
[TBL] [Abstract][Full Text] [Related]
10. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment in Poland and Scotland: comparison of process and decisions.
Kolasa K; Wasiak R
Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
[TBL] [Abstract][Full Text] [Related]
12. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
Malinowski KP; Kawalec P; Trąbka W
Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
[TBL] [Abstract][Full Text] [Related]
13. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
Allen N; Liberti L; Walker SR; Salek S
Front Pharmacol; 2017; 8():384. PubMed ID: 28713265
[No Abstract] [Full Text] [Related]
15. Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015.
Ozierański P; Löblová O; Nicholls N; Csanádi M; Kaló Z; McKee M; King L
Health Econ Policy Law; 2019 Apr; 14(2):182-204. PubMed ID: 29307327
[TBL] [Abstract][Full Text] [Related]
16. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
17. Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines.
Lach K; Dziwisz M; Rémuzat C; Toumi M
J Mark Access Health Policy; 2017; 5(1):1355202. PubMed ID: 28804603
[No Abstract] [Full Text] [Related]
18. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
19. Health technology assessment of public health programmes in Poland, years 2010 and 2013.
Kolasa K; Turlej A; Hermanowski T
Przegl Epidemiol; 2016; 70(1):77-81, 151-4. PubMed ID: 27344479
[TBL] [Abstract][Full Text] [Related]
20. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
